Korean J Dermatol.  2022 Feb;60(2):106-110.

CD30 Large-Cell Transformation of Mycosis Fungoides Treated with Brentuximab Vedotin

  • 1Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  • 2Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
  • 3Biomedical Research Institute, Pusan National University Hospital, Busan, Korea


Large-cell transformation of mycosis fungoides (LCT-MF) is an advanced stage of primary cutaneous T-cell lymphoma with a poor prognosis. Therapeutic options for these patients are often limited, and so far, they are not promising. An 81-year-old woman with a previous history of mycosis fungoides presented with aggravation of generalized erythematous scaly patches and new onset of ulcerated tumor on the abdomen for 3 months. Histopathological examination revealed a dense dermal infiltrate composed of atypical large lymphocytes. Immunohistochemically, the tumor cells were positive for CD30 expression. A diagnosis of CD30 LCT-MF was established. She was intensively treated with methotrexate (1 month), acitretin (1 month), and rituximab with dose-modified cyclophosphamide, doxorubicin, and prednisone (1 cycle). Despite such treatments, the improvement was minimal. Subsequently, the patient was started on brentuximab vedotin, 1.8 mg/kg intravenously once every 3 weeks. She responded well to brentuximab therapy, and the skin lesions completely subsided within 12 weeks of treatment.


Cutaneous T-cell lymphoma; Mycosis fungoides
Full Text Links
  • KJD
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr